Gilead Sciences, Inc. (NASDAQ:GILD) Stake Lessened by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 178,189 shares of the biopharmaceutical company’s stock after selling 7,222 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Gilead Sciences were worth $13,052,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Private Wealth Management Group LLC bought a new position in Gilead Sciences during the fourth quarter worth $29,000. Palisade Asset Management LLC bought a new position in shares of Gilead Sciences in the 1st quarter worth about $29,000. Sachetta LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $30,000. Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $33,000. Finally, Gladius Capital Management LP acquired a new stake in Gilead Sciences during the fourth quarter worth about $34,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on GILD shares. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a report on Monday, July 8th. TD Cowen dropped their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research report on Monday, July 1st. Twelve equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $81.81.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Up 0.9 %

GILD opened at $77.73 on Tuesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The company has a market capitalization of $96.84 billion, a PE ratio of 215.92, a P/E/G ratio of 3.28 and a beta of 0.18. The stock’s fifty day moving average is $67.99 and its 200-day moving average is $70.93. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.